Neuroprotection by Novel Regulators of mGluR Signaling

mGluR 信号传导的新型调节剂的神经保护作用

基本信息

项目摘要

DESCRIPTION (provided by applicant): Glutamate activates ionotropic glutamate receptors (iGluRs) that mediate fast synaptic transmission, and metabotropic glutamate receptors (mGluRs) that modulate cell excitability. The iGluRs gate extracellular sodium and calcium entry into the cell, while the Group I mGluRs (1, 5) lead to the release of calcium from intracellular stores. Brain injury such as stroke or ischemia leads to increased extracellular glutamate, uncontrolled activation of iGluRs and mGluRs, and the toxic accumulation of intracellular calcium that is an essential initiator of cell death. Thus therapeutic strategies for the treatment of brain ischemia have focused on the use of iGluR and Group I mGluR antagonists. While iGluR antagonists are neuroprotective in modeled ischemia studies, likely due to inhibition of intracellular calcium accumulation, these compounds have failed in clinical trials. Similarly, Group I mGluR antagonists are neuroprotective in modeled ischemia studies, likely due to inhibition of intracellular calcium accumulation, yet delivery of most mGluR-selective compounds to the brain is difficult. We have begun to explore alternative neuroprotective strategies for brain ischemia using proteomics to identify novel proteins or peptides that modulate Group I mGluR signaling via interactions at the pharmacologically accessible extracellular amino terminal domain. Our first proteomic studies focused on the Group I mGluR subtype, mGluRS, and revealed a novel interaction with a recently cloned extracellular protein that promotes cell survival, ADNP (activity-dependent neuroprotective protein). ADNP contains an eight amino acid peptide sequence (NAPVSIPQ; NAP) that was shown to be the smallest active element of ADNP that can induce neuroprotection. Preclinical experiments show that NAP has potent neuroprotective, memory enhancing and neurotrophic properties. However, the mechanisms that underlie neuroprotection by NAP or ADNP are not known. Our preliminary data suggest that one mechanism of neuroprotection by NAP and ADNP is to regulate Group I mGluR signaling. The research studies proposed herein are important because 1) they begin to delineate the mechanisms of neuroprotection by NAP, an exogenous peptide, and ADNP, an endogenous protein, 2) they provide evidence for the novel regulation of mGluR signaling by peptide or protein interactions at the extracellular domain, and 3) they offer new approaches for therapeutic intervention in brain ischemia.
描述(由申请人提供):谷氨酸激活介导快速突触传递的离子型谷氨酸受体(iGluR)和调节细胞兴奋性的代谢型谷氨酸受体(mGluR)。iGluR门控细胞外钠和钙进入细胞,而I组mGluR(1,5)导致钙从细胞内储存释放。脑损伤如中风或缺血导致细胞外谷氨酸盐增加、iGluR和mGluR的不受控制的激活以及细胞内钙的毒性积累,这是细胞死亡的基本引发剂。因此,用于治疗脑缺血的治疗策略集中于使用iGluR和I组mGluR拮抗剂。虽然iGluR拮抗剂在模拟缺血研究中具有神经保护作用,可能是由于抑制细胞内钙积累,但这些化合物在临床试验中失败。类似地,I组mGluR拮抗剂在模拟缺血研究中具有神经保护性,这可能是由于抑制细胞内钙积累,但将大多数mGluR选择性化合物递送至脑是困难的。我们已经开始探索脑缺血的替代神经保护策略,使用蛋白质组学来鉴定通过在可接近的胞外氨基末端结构域的相互作用来调节I组mGluR信号传导的新蛋白质或肽。我们的第一个蛋白质组学研究集中在第一组mGluR亚型,mGluRS,并揭示了一种新的相互作用与最近克隆的细胞外蛋白,促进细胞存活,ADNP(活性依赖性神经保护蛋白)。ADNP含有8个氨基酸的肽序列(NAPVSIPQ; NAP),其被证明是ADNP中可以诱导神经保护的最小活性元件。临床前实验表明,NAP具有有效的神经保护,记忆增强和神经营养特性。然而,NAP或ADNP的神经保护机制尚不清楚。我们的初步数据表明,NAP和ADNP的神经保护机制之一是调节I组mGluR信号。本文提出的研究是重要的,因为1)它们开始描绘NAP(一种外源肽)和ADNP(一种内源蛋白)的神经保护机制,2)它们提供了通过胞外结构域的肽或蛋白相互作用对mGluR信号传导进行新调节的证据,以及3)它们提供了脑缺血治疗干预的新方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JULIE Anne SAUGSTAD其他文献

JULIE Anne SAUGSTAD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JULIE Anne SAUGSTAD', 18)}}的其他基金

Human Cerebrospinal Fluid Extracellular Vesicles: Utility as Disease Specific Biomarkers and Impact on Alzheimer's Disease Pathology
人脑脊液细胞外囊泡:作为疾病特异性生物标志物的用途及其对阿尔茨海默病病理学的影响
  • 批准号:
    10661249
  • 财政年份:
    2023
  • 资助金额:
    $ 31.39万
  • 项目类别:
MicroRNA-Mediated Translation Initiation Arrest In Ischemic Brain
缺血性脑中 MicroRNA 介导的翻译启动停滞
  • 批准号:
    8637416
  • 财政年份:
    2013
  • 资助金额:
    $ 31.39万
  • 项目类别:
MicroRNA-Mediated Translation Initiation Arrest In Ischemic Brain
缺血性脑中 MicroRNA 介导的翻译启动停滞
  • 批准号:
    8729036
  • 财政年份:
    2013
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role for MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    8452749
  • 财政年份:
    2010
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role for MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    8250394
  • 财政年份:
    2010
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role for MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    8046406
  • 财政年份:
    2010
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role for MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    7890326
  • 财政年份:
    2010
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role of MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    7273884
  • 财政年份:
    2006
  • 资助金额:
    $ 31.39万
  • 项目类别:
Role of MicroRNAs in Ischemic Tolerance
MicroRNA 在缺血耐受中的作用
  • 批准号:
    7147082
  • 财政年份:
    2006
  • 资助金额:
    $ 31.39万
  • 项目类别:
Neuroprotection by Novel Regulators of mGluR Signaling
mGluR 信号传导的新型调节剂的神经保护作用
  • 批准号:
    7341708
  • 财政年份:
    2005
  • 资助金额:
    $ 31.39万
  • 项目类别:

相似海外基金

Elucidating the universality and specificity of reproductive mechanisms between species using genetically modified animals
使用转基因动物阐明物种间生殖机制的普遍性和特异性
  • 批准号:
    21H02397
  • 财政年份:
    2021
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Molecular cytological clarification of pathogenesis of male infertility by analyzing genetically modified animals and its clinical application
转基因动物分子细胞学阐明男性不育发病机制及其临床应用
  • 批准号:
    19K09665
  • 财政年份:
    2019
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the processing mechanism of reactive oxygen species in the inner ear in MnSOD genetically modified animals
阐明MnSOD转基因动物内耳活性氧的加工机制
  • 批准号:
    15H06174
  • 财政年份:
    2015
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Analysis of mammalian germ cell-specific GPI-anchored proteins using genetically modified animals
使用转基因动物分析哺乳动物生殖细胞特异性 GPI 锚定蛋白
  • 批准号:
    15H05573
  • 财政年份:
    2015
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
Research on the apelin as a therapeutic target molecule in ischemic retinopathy using genetically modified animals
使用转基因动物进行 apelin 作为缺血性视网膜病变治疗靶分子的研究
  • 批准号:
    24590131
  • 财政年份:
    2012
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of D-serine-related gene and elucidation of etiology of schizophrenia using genetically modified animals
利用转基因动物鉴定D-丝氨酸相关基因并阐明精神分裂症的病因
  • 批准号:
    21590292
  • 财政年份:
    2009
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular and morphological analysis of RNA helicase that shows an unique expression in the nervous system by utilizing genetically modified animals
利用转基因动物对 RNA 解旋酶进行分子和形态学分析,该酶在神经系统中显示出独特的表达
  • 批准号:
    21590198
  • 财政年份:
    2009
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Research on the onset and progression of amyotrophic lateral sclerosis using genetically modified animals
使用转基因动物研究肌萎缩侧索硬化症的发病和进展
  • 批准号:
    21590110
  • 财政年份:
    2009
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Study on cell-specific roles of nudear factor KB in the progression of renal diseases with genetically modified animals
核因子KB在转基因动物肾脏疾病进展中的细胞特异性作用研究
  • 批准号:
    18590903
  • 财政年份:
    2006
  • 资助金额:
    $ 31.39万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了